Join the members group    Follow Us

FPM Conversations

About Faculty Conversations

Faculty conversations are designed to give members the unique opportunity to engage with eminent figures in industry, government, regulation, academia and clinical practice. The evenings consist of a buffet dinner, followed by around 1½ hours of discussion and debate, with drinks and networking to finish - a perfect combination of the professional and the social.

If you have any thoughts or ideas on who could lead conversations and on what topics then please get in touch with us (

Our last event:

Should Pharma pay doctors?

Date: 20th March 2019, 6.30pm

Increasing scrutiny on the relationship between prescribers and industry on the development, promotion and utilisation of medicines, has led to a evolution in standards of practice and rules of engagement. In spite of this there remains significant concern amongst healthcare professionals (HCPs) and professional bodies as to how these relationships are managed. A number of recent cases have also brought about increasingly negative media attention.

Focussing on real world case studies, we explored the past, present and future of how pharmaceutical companies engage HCPs. The session highlighted areas of particular risk and illustrate how HCP engagement can be done appropriately and how pharmaceutical physicians can make a positive impact on decisions.

Venue: Voysey Room, Mary Ward House Conference and Exhibition Centre,
5 - 7 Tavistock Place London, WC1H 9SN


The panellists - Faisal Mehmud and Karen Mullen


Faisal joined Bristol-Myers Squibb (BMS) in July 2016 initially to lead the UK and Ireland Medical organisation, and now heads the European Medical group.

He has held a variety of senior leadership roles, most recently at Novartis in the USA, where he was the Vice President of US Clinical Development and Medical Affairs Oncology.  Previously he was at GSK, where he was Head of the USA North American Medical Affairs/Clinical Development group for Oncology & Haematology and prior to this he held several roles of increasing seniority at GSK and at Sanofi.

He has extensive experience in late phase drug development, interaction with regulators, HTA bodies and academic co-operative groups globally over 15 years in a variety of therapeutic areas.

Faisal graduated in Medicine from Cambridge University, and before his time in industry, was a practicing physician in the UK in general medicine and oncology. 


Karen is Country Medical Director of GSK for UK and Ireland.

Worked in pharmaceutical medicine for 18 years across Medical Affairs, Clinical Research and Development.

Karen has worked across several therapy areas including general medicine, vaccines, gene therapy, she has worked in Australia and USA.

Last November she gave one of the plenary presentations, on the reinvention of the medical department at FPM Annual Symposium 2018.